-
1
-
-
63249126579
-
Targeting hepatic glucokinase in type 2 diabetes: Weighing the benefits and risks
-
Agius L, (2009). Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks. Diabetes 58: 18-20.
-
(2009)
Diabetes
, vol.58
, pp. 18-20
-
-
Agius, L.1
-
2
-
-
64049110523
-
Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis
-
Arendt BM, Mohammed SS, Aghdassi E, Prayitno NR, Ma DW, Nguyen A, et al,. (2009). Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis. J Nutr 139: 691-695.
-
(2009)
J Nutr
, vol.139
, pp. 691-695
-
-
Arendt, B.M.1
Mohammed, S.S.2
Aghdassi, E.3
Prayitno, N.R.4
Ma, D.W.5
Nguyen, A.6
-
3
-
-
70349641037
-
Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes
-
Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, et al,. (2009). Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem 52: 6142-6152.
-
(2009)
J Med Chem
, vol.52
, pp. 6142-6152
-
-
Bebernitz, G.R.1
Beaulieu, V.2
Dale, B.A.3
Deacon, R.4
Duttaroy, A.5
Gao, J.6
-
4
-
-
70349980881
-
The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase in liver
-
Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, Orho-Melander M, et al,. (2009). The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase in liver. Hum Mol Genet 18: 4081-4088.
-
(2009)
Hum Mol Genet
, vol.18
, pp. 4081-4088
-
-
Beer, N.L.1
Tribble, N.D.2
McCulloch, L.J.3
Roos, C.4
Johnson, P.R.5
Orho-Melander, M.6
-
5
-
-
0033800945
-
Rapid assessment of drug metabolism in the drug discovery process
-
Bertand M, Jackson P, Walther B, (2000). Rapid assessment of drug metabolism in the drug discovery process. Eur J Pharm Sci 11 (Suppl. 2): S61-S72.
-
(2000)
Eur J Pharm Sci
, vol.11
, Issue.SUPPL. 2
-
-
Bertand, M.1
Jackson, P.2
Walther, B.3
-
6
-
-
47749124955
-
SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: Discovery of PSN-GK1
-
Bertram LS, Black D, Briner PH, Chatfield R, Cooke A, Fyfe MC, et al,. (2008). SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1. J Med Chem 51: 4340-4345.
-
(2008)
J Med Chem
, vol.51
, pp. 4340-4345
-
-
Bertram, L.S.1
Black, D.2
Briner, P.H.3
Chatfield, R.4
Cooke, A.5
Fyfe, M.C.6
-
7
-
-
77955398001
-
Association of rs780094 in GCKR with metabolic traits and incident diabetes and cardiovascular disease: The ARIC study
-
Bi M, Kao WH, Boerwinkle E, Hoogeveen RC, Rasmussen-Torvik LJ, Astor BC, et al,. (2010). Association of rs780094 in GCKR with metabolic traits and incident diabetes and cardiovascular disease: the ARIC study. Plos ONE 5: e11690.
-
(2010)
Plos ONE
, vol.5
-
-
Bi, M.1
Kao, W.H.2
Boerwinkle, E.3
Hoogeveen, R.C.4
Rasmussen-Torvik, L.J.5
Astor, B.C.6
-
8
-
-
10744224346
-
Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators
-
Brocklehurst KJ, Payne VA, Davies RA, Carroll D, Vertigan HL, Wightman HJ, et al,. (2004). Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes 53: 535-541.
-
(2004)
Diabetes
, vol.53
, pp. 535-541
-
-
Brocklehurst, K.J.1
Payne, V.A.2
Davies, R.A.3
Carroll, D.4
Vertigan, H.L.5
Wightman, H.J.6
-
9
-
-
79959517565
-
Human fatty liver disease: Old questions and new insights
-
Cohen JC, Horton JD, Hobbs HH, (2011). Human fatty liver disease: old questions and new insights. Science 332: 1519-1523.
-
(2011)
Science
, vol.332
, pp. 1519-1523
-
-
Cohen, J.C.1
Horton, J.D.2
Hobbs, H.H.3
-
10
-
-
33748989539
-
Predictive blood glucose lowering efficacy by glucokinase activators in high fat fed female Zucker rats
-
Coope GJ, Atkinson AM, Allott C, McKerrecher D, Johnstone C, Pike KG, et al,. (2006). Predictive blood glucose lowering efficacy by glucokinase activators in high fat fed female Zucker rats. Br J Pharmacol 149: 328-335.
-
(2006)
Br J Pharmacol
, vol.149
, pp. 328-335
-
-
Coope, G.J.1
Atkinson, A.M.2
Allott, C.3
McKerrecher, D.4
Johnstone, C.5
Pike, K.G.6
-
11
-
-
81555204236
-
Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs
-
Eiki J, Nagata Y, Futamura M, Sasaki-Yamamoto K, Iino T, Nishimura T, et al,. (2011). Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. Mol Pharmacol 80: 1156-1165.
-
(2011)
Mol Pharmacol
, vol.80
, pp. 1156-1165
-
-
Eiki, J.1
Nagata, Y.2
Futamura, M.3
Sasaki-Yamamoto, K.4
Iino, T.5
Nishimura, T.6
-
12
-
-
0347477364
-
Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance
-
Ferre T, Riu E, Franckhauser S, Agudo J, Bosch F, (2003). Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance. Diabetologia 46: 1662-1668.
-
(2003)
Diabetologia
, vol.46
, pp. 1662-1668
-
-
Ferre, T.1
Riu, E.2
Franckhauser, S.3
Agudo, J.4
Bosch, F.5
-
13
-
-
70449158340
-
A simple method for the isolation and purification of total lipides from animal tissues
-
Folch J, Lees M, Sloane Stanley GH, (1957). A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.
-
(1957)
J Biol Chem
, vol.226
, pp. 497-509
-
-
Folch, J.1
Lees, M.2
Sloane Stanley, G.H.3
-
14
-
-
0026608764
-
Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus
-
Froguel P, Vaxillaire M, Sun F, Velho G, Zouali H, Butel MO, et al,. (1992). Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 356: 162-164.
-
(1992)
Nature
, vol.356
, pp. 162-164
-
-
Froguel, P.1
Vaxillaire, M.2
Sun, F.3
Velho, G.4
Zouali, H.5
Butel, M.O.6
-
15
-
-
84862826583
-
Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat
-
Futamura M, Yao J, Li X, Bergeron R, Tran JL, Zycband E, et al,. (2012). Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat. Diabetologia 55: 1071-1080.
-
(2012)
Diabetologia
, vol.55
, pp. 1071-1080
-
-
Futamura, M.1
Yao, J.2
Li, X.3
Bergeron, R.4
Tran, J.L.5
Zycband, E.6
-
16
-
-
0032556969
-
Familial hyperinsulinism caused by an activating glucokinase mutation
-
Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, et al,. (1998). Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 338: 226-230.
-
(1998)
N Engl J Med
, vol.338
, pp. 226-230
-
-
Glaser, B.1
Kesavan, P.2
Heyman, M.3
Davis, E.4
Cuesta, A.5
Buchs, A.6
-
17
-
-
0041319267
-
Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations
-
Gloyn AL, Noordam K, Willemsen MA, Ellard S, Lam WW, Campbell IW, et al,. (2003). Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 52: 2433-2440.
-
(2003)
Diabetes
, vol.52
, pp. 2433-2440
-
-
Gloyn, A.L.1
Noordam, K.2
Willemsen, M.A.3
Ellard, S.4
Lam, W.W.5
Campbell, I.W.6
-
18
-
-
0037624071
-
Allosteric activators of glucokinase: Potential role in diabetes therapy
-
Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, et al,. (2003). Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301: 370-373.
-
(2003)
Science
, vol.301
, pp. 370-373
-
-
Grimsby, J.1
Sarabu, R.2
Corbett, W.L.3
Haynes, N.E.4
Bizzarro, F.T.5
Coffey, J.W.6
-
19
-
-
1542791635
-
Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase
-
Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y, (2004). Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 12: 429-438.
-
(2004)
Structure
, vol.12
, pp. 429-438
-
-
Kamata, K.1
Mitsuya, M.2
Nishimura, T.3
Eiki, J.4
Nagata, Y.5
-
20
-
-
77954326944
-
NC3Rs Reporting Guidelines Working Group
-
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
-
(2010)
Br J Pharmacol
, vol.160
, pp. 1577-1579
-
-
Kilkenny, C.1
Browne, W.2
Cuthill, I.C.3
Emerson, M.4
Altman, D.G.5
-
21
-
-
63249121641
-
Hepatic steraoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver
-
Kotronen A, Seppanen-Laasko T, Westerbacka J, Kiviluoto T, Arola J, Ruskeepaa AL, et al,. (2009). Hepatic steraoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 58: 203-208.
-
(2009)
Diabetes
, vol.58
, pp. 203-208
-
-
Kotronen, A.1
Seppanen-Laasko, T.2
Westerbacka, J.3
Kiviluoto, T.4
Arola, J.5
Ruskeepaa, A.L.6
-
22
-
-
33645896147
-
Design of a potent, soluble glucokinase activator with excellent in vivo efficacy
-
McKerrecher D, Allen JV, Caulkett PW, Donald CS, Fenwick ML, Grange E, et al,. (2006). Design of a potent, soluble glucokinase activator with excellent in vivo efficacy. Bioorg Med Chem Lett 16: 2705-2709.
-
(2006)
Bioorg Med Chem Lett
, vol.16
, pp. 2705-2709
-
-
McKerrecher, D.1
Allen, J.V.2
Caulkett, P.W.3
Donald, C.S.4
Fenwick, M.L.5
Grange, E.6
-
23
-
-
0032880513
-
Structural model of human glucokinase in complex with glucose and ATP: Implications for the mutants that cause hypo- and hyperglycemia
-
Mahalingam B, Cuesta-Munoz A, Davis EA, Matschinsky FM, Harrison RW, Weber IT, (1999). Structural model of human glucokinase in complex with glucose and ATP: implications for the mutants that cause hypo- and hyperglycemia. Diabetes 48: 1698-1705.
-
(1999)
Diabetes
, vol.48
, pp. 1698-1705
-
-
Mahalingam, B.1
Cuesta-Munoz, A.2
Davis, E.A.3
Matschinsky, F.M.4
Harrison, R.W.5
Weber, I.T.6
-
24
-
-
67349139275
-
Assessing the potential of glucokinase activators in diabetes therapy
-
Matschinsky FM, (2009). Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8: 399-416.
-
(2009)
Nat Rev Drug Discov
, vol.8
, pp. 399-416
-
-
Matschinsky, F.M.1
-
25
-
-
79955605398
-
Research and development of glucokinase activators for diabetes therapy: Theoretical and practical aspects
-
Matschinsky FM, Zelent B, Doliba NM, Kaestner KH, Vanderkooi JM, Grimsby J, et al,. (2011). Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects. Handb Exp Pharmacol 203: 357-401.
-
(2011)
Handb Exp Pharmacol
, vol.203
, pp. 357-401
-
-
Matschinsky, F.M.1
Zelent, B.2
Doliba, N.M.3
Kaestner, K.H.4
Vanderkooi, J.M.5
Grimsby, J.6
-
26
-
-
77954331629
-
Guidelines for reporting experiments involving animals: The ARRIVE guidelines
-
McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
-
(2010)
Br J Pharmacol
, vol.160
, pp. 1573-1576
-
-
McGrath, J.1
Drummond, G.2
Kilkenny, C.3
Wainwright, C.4
-
27
-
-
81555210580
-
Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes
-
Meininger GE, Scott R, Alba M, Shentu Y, Luo E, Amin H, et al,. (2011). Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 34: 2560-2566.
-
(2011)
Diabetes Care
, vol.34
, pp. 2560-2566
-
-
Meininger, G.E.1
Scott, R.2
Alba, M.3
Shentu, Y.4
Luo, E.5
Amin, H.6
-
28
-
-
0842291578
-
Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells
-
Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P, (2004). Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology 145: 667-678.
-
(2004)
Endocrinology
, vol.145
, pp. 667-678
-
-
Merglen, A.1
Theander, S.2
Rubi, B.3
Chaffard, G.4
Wollheim, C.B.5
Maechler, P.6
-
29
-
-
79952457093
-
Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease
-
Miller MH, Ferguson MAJ, Dillon JF, (2011). Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. Liver Int 31: 461-473.
-
(2011)
Liver Int
, vol.31
, pp. 461-473
-
-
Miller, M.H.1
Ferguson, M.A.J.2
Dillon, J.F.3
-
30
-
-
84860469242
-
Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease
-
Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, et al,. (2012). Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 15: 665-674.
-
(2012)
Cell Metab
, vol.15
, pp. 665-674
-
-
Min, H.K.1
Kapoor, A.2
Fuchs, M.3
Mirshahi, F.4
Zhou, H.5
Maher, J.6
-
31
-
-
0342902204
-
Neonatal diabetes mellitus due to complete glucokinase deficiency
-
NjÃlstad PR, SÃvik O, Cuesta-Muñoz A, BjÃrkhaug L, Massa O, Barbetti F, et al,. (2001). Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 344: 1588-1592.
-
(2001)
N Engl J Med
, vol.344
, pp. 1588-1592
-
-
Njãlstad, P.R.1
Sãvik, O.2
Cuesta-Muñoz, A.3
Bjãrkhaug, L.4
Massa, O.5
Barbetti, F.6
-
32
-
-
79960202841
-
Type 2 diabetes across generations: From pathophysiology to prevention and management
-
Nolan CJ, Damm P, Prentki M, (2011). Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 378: 169-181.
-
(2011)
Lancet
, vol.378
, pp. 169-181
-
-
Nolan, C.J.1
Damm, P.2
Prentki, M.3
-
33
-
-
0032884829
-
Metabolic impact of glucokinase overexpression in liver: Lowering of blood glucose in fed rats is accompanied by hyperlipidemia
-
O'Doherty RM, Lehman DL, Télémaque-Potts S, Newgard CB, (1999). Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 48: 2022-2027.
-
(1999)
Diabetes
, vol.48
, pp. 2022-2027
-
-
O'Doherty, R.M.1
Lehman, D.L.2
Télémaque-Potts, S.3
Newgard, C.B.4
-
34
-
-
54249088172
-
Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations
-
Orho-Melander M, Melander O, Guiducci C, Perez-Martinez P, Corella D, Roos C, et al,. (2008). Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57: 3112-3121.
-
(2008)
Diabetes
, vol.57
, pp. 3112-3121
-
-
Orho-Melander, M.1
Melander, O.2
Guiducci, C.3
Perez-Martinez, P.4
Corella, D.5
Roos, C.6
-
35
-
-
70350741368
-
Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia
-
Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanné-Chantelot C, Ellard S, et al,. (2009). Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 30: 1512-1526.
-
(2009)
Hum Mutat
, vol.30
, pp. 1512-1526
-
-
Osbak, K.K.1
Colclough, K.2
Saint-Martin, C.3
Beer, N.L.4
Bellanné- Chantelot, C.5
Ellard, S.6
-
36
-
-
79951649407
-
Recent advances in imaging hepatic fibrosis and steatosis
-
Patel KD, Abeysekera KW, Marlais M, McPhail MJ, Thomas HC, Fitzpatrick JA, et al,. (2011). Recent advances in imaging hepatic fibrosis and steatosis. Expert Rev Gastroenterol Hepatol 5: 91-104.
-
(2011)
Expert Rev Gastroenterol Hepatol
, vol.5
, pp. 91-104
-
-
Patel, K.D.1
Abeysekera, K.W.2
Marlais, M.3
McPhail, M.J.4
Thomas, H.C.5
Fitzpatrick, J.A.6
-
37
-
-
79960086105
-
Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans
-
Peter A, Stefan N, Cegan A, Walenta M, Wagner S, Königsrainer A, et al,. (2011). Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 96: E1126-E1130.
-
(2011)
J Clin Endocrinol Metab
, vol.96
-
-
Peter, A.1
Stefan, N.2
Cegan, A.3
Walenta, M.4
Wagner, S.5
Königsrainer, A.6
-
38
-
-
80955139676
-
The active conformation of human glucokinase is not altered by allosteric activators
-
Petit P, Antoine M, Ferry G, Boutin JA, Lagarde A, Gluais L, et al,. (2011). The active conformation of human glucokinase is not altered by allosteric activators. Acta Cryst D 67: 929-935.
-
(2011)
Acta Cryst
, vol.67
, pp. 929-935
-
-
Petit, P.1
Antoine, M.2
Ferry, G.3
Boutin, J.A.4
Lagarde, A.5
Gluais, L.6
-
39
-
-
34250373752
-
Glucokinase thermolability and hepatic regulatory protein binding are essential factors for predicting the blood glucose phenotype of missense mutations
-
Pino MF, Kim KA, Shelton KD, Lindner J, Odili S, Li C, et al,. (2007). Glucokinase thermolability and hepatic regulatory protein binding are essential factors for predicting the blood glucose phenotype of missense mutations. J Biol Chem 282: 13906-13916.
-
(2007)
J Biol Chem
, vol.282
, pp. 13906-13916
-
-
Pino, M.F.1
Kim, K.A.2
Shelton, K.D.3
Lindner, J.4
Odili, S.5
Li, C.6
-
40
-
-
40549135297
-
Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice
-
Postic C, Girard J, (2008). Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118: 829-838.
-
(2008)
J Clin Invest
, vol.118
, pp. 829-838
-
-
Postic, C.1
Girard, J.2
-
41
-
-
0035787576
-
Cell-specific roles of glucokinase in glucose homeostasis
-
Postic C, Shiota M, Magnuson MA, (2001). Cell-specific roles of glucokinase in glucose homeostasis. Recent Prog Horm Res 56: 195-217.
-
(2001)
Recent Prog Horm Res
, vol.56
, pp. 195-217
-
-
Postic, C.1
Shiota, M.2
Magnuson, M.A.3
-
42
-
-
79953246834
-
Hepatic steatosis and type 2 diabetes: Current and future treatment considerations
-
Richard J, Lingvay I, (2011). Hepatic steatosis and type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther 9: 321-328.
-
(2011)
Expert Rev Cardiovasc Ther
, vol.9
, pp. 321-328
-
-
Richard, J.1
Lingvay, I.2
-
43
-
-
33745107554
-
Mechanisms of disease: Hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance
-
Roden M, (2006). Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2: 335-348.
-
(2006)
Nat Clin Pract Endocrinol Metab
, vol.2
, pp. 335-348
-
-
Roden, M.1
-
44
-
-
77953868236
-
Lipid-induced insulin resistance: Unravelling the mechanism
-
Samuel VT, Petersen KF, Shulman GI, (2010). Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375: 2267-2277.
-
(2010)
Lancet
, vol.375
, pp. 2267-2277
-
-
Samuel, V.T.1
Petersen, K.F.2
Shulman, G.I.3
-
45
-
-
84857398069
-
Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents
-
Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R, et al,. (2012). Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 55: 781-789.
-
(2012)
Hepatology
, vol.55
, pp. 781-789
-
-
Santoro, N.1
Zhang, C.K.2
Zhao, H.3
Pakstis, A.J.4
Kim, G.5
Kursawe, R.6
-
46
-
-
78650501835
-
Novel glucokinase activators: A patent review (2008-2010)
-
Sarabu R, Berthel SJ, Kester RF, Tilley JW, (2011). Novel glucokinase activators: a patent review (2008-2010). Expert Opin Ther Pat 21: 13-33.
-
(2011)
Expert Opin Ther Pat
, vol.21
, pp. 13-33
-
-
Sarabu, R.1
Berthel, S.J.2
Kester, R.F.3
Tilley, J.W.4
-
47
-
-
34249888775
-
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
-
Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, et al,. (2007). Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316: 1331-1336.
-
(2007)
Science
, vol.316
, pp. 1331-1336
-
-
Saxena, R.1
Voight, B.F.2
Lyssenko, V.3
Burtt, N.P.4
De Bakker, P.I.5
Chen, H.6
-
48
-
-
0017101039
-
Preparation of isolated rat liver cells
-
Prescott D.M. (ed.). Ch. 4. Academic Press: New York
-
Seglen PO, (1976). Preparation of isolated rat liver cells. In:, Prescott DM, (ed.). Methods in Cell Biology, Vol. XIII. Ch. 4. Academic Press: New York, pp. 29-83.
-
(1976)
Methods in Cell Biology
, vol.13
, pp. 29-83
-
-
Seglen, P.O.1
-
49
-
-
79960847840
-
Nonalcoholic fatty liver disease and diabetes mellitus: Pathogenesis and treatment
-
Smith BW, Adams LA, (2011). Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 7: 456-465.
-
(2011)
Nat Rev Endocrinol
, vol.7
, pp. 456-465
-
-
Smith, B.W.1
Adams, L.A.2
-
50
-
-
57349116780
-
Causes and metabolic consequences of fatty liver
-
Stefan N, Kantartzis K, Häring HU, (2008). Causes and metabolic consequences of fatty liver. Endocr Rev 29: 939-960.
-
(2008)
Endocr Rev
, vol.29
, pp. 939-960
-
-
Stefan, N.1
Kantartzis, K.2
Häring, H.U.3
-
51
-
-
12144259379
-
Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population
-
Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al,. (2005). Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288: E462-E468.
-
(2005)
Am J Physiol Endocrinol Metab
, vol.288
-
-
Szczepaniak, L.S.1
Nurenberg, P.2
Leonard, D.3
Browning, J.D.4
Reingold, J.S.5
Grundy, S.6
-
52
-
-
33746597352
-
Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes
-
Toledo FGS, Sniderman AD, Kelley DE, (2006). Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 29: 1845-1850.
-
(2006)
Diabetes Care
, vol.29
, pp. 1845-1850
-
-
Toledo, F.G.S.1
Sniderman, A.D.2
Kelley, D.E.3
-
53
-
-
0032723877
-
Differences in signaling properties of the cytoplasmic domains of the insulin receptor and insulin-like growth factor Receptor in 3T3-L1 adipocytes
-
Ursà B, Cope DL, Kalloo-Hosein HE, Hayward AC, Whitehead JP, O'Rahilly S, et al,. (1999). Differences in signaling properties of the cytoplasmic domains of the insulin receptor and insulin-like growth factor Receptor in 3T3-L1 adipocytes. J Biol Chem 274: 30864-30873.
-
(1999)
J Biol Chem
, vol.274
, pp. 30864-30873
-
-
Ursã, B.1
Cope, D.L.2
Kalloo-Hosein, H.E.3
Hayward, A.C.4
Whitehead, J.P.5
O'Rahilly, S.6
-
54
-
-
36549039503
-
Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycemia of infancy
-
Wabitsch M, Lahr G, Van de Bunt M, Marchant C, Lindner M, von Puttkamer J, et al,. (2007). Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycemia of infancy. Diabet Med 24: 1393-1399.
-
(2007)
Diabet Med
, vol.24
, pp. 1393-1399
-
-
Wabitsch, M.1
Lahr, G.2
Van De Bunt, M.3
Marchant, C.4
Lindner, M.5
Von Puttkamer, J.6
-
55
-
-
38649125868
-
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
-
Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al,. (2008). Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40: 161-169.
-
(2008)
Nat Genet
, vol.40
, pp. 161-169
-
-
Willer, C.J.1
Sanna, S.2
Jackson, A.U.3
Scuteri, A.4
Bonnycastle, L.L.5
Clarke, R.6
-
56
-
-
79959308013
-
Chronic glucokinase activation reduces glycemia and improves glucose tolerance in high-fat diet fed mice
-
Winzell MS, Coghlan M, Leighton B, Frangioudakis G, Smith DM, Storlien LH, et al,. (2011). Chronic glucokinase activation reduces glycemia and improves glucose tolerance in high-fat diet fed mice. Eur J Pharmacol 663: 80-86.
-
(2011)
Eur J Pharmacol
, vol.663
, pp. 80-86
-
-
Winzell, M.S.1
Coghlan, M.2
Leighton, B.3
Frangioudakis, G.4
Smith, D.M.5
Storlien, L.H.6
-
57
-
-
0030990079
-
In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - Fact or myth
-
Yee S, (1997). In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res 14: 763-766.
-
(1997)
Pharm Res
, vol.14
, pp. 763-766
-
-
Yee, S.1
|